Tower Research Capital (TRC)’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $589K | Sell |
1,585
-733
| -32% | -$219K | 0.01% | 921 |
|
|
2026
Q1 | $599K | Buy |
2,318
+632
| +37% | +$168K | 0.02% | 799 |
|
|
2025
Q4 | $416K | Buy |
1,686
+693
| +70% | +$146K | 0.01% | 935 |
|
|
2025
Q3 | $175K | Sell |
993
-2,005
| -67% | -$300K | ﹤0.01% | 1573 |
|
|
2025
Q2 | $412K | Buy |
2,998
+2,268
| +311% | +$333K | 0.01% | 1148 |
|
|
2025
Q1 | $132K | Sell |
730
-6,269
| -90% | -$1.05M | ﹤0.01% | 1616 |
|
|
2024
Q4 | $1.1M | Buy |
6,999
+6,912
| +7,945% | +$1.23M | 0.02% | 581 |
|
|
2024
Q3 | $15.8K | Sell |
87
-2,115
| -96% | -$408K | ﹤0.01% | 3394 |
|
|
2024
Q2 | $404K | Buy |
2,202
+565
| +35% | +$94.9K | 0.01% | 1513 |
|
|
2024
Q1 | $291K | Buy |
1,637
+381
| +30% | +$52.9K | 0.01% | 1180 |
|
|
2023
Q4 | $156K | Sell |
1,256
-350
| -22% | -$38.8K | ﹤0.01% | 2290 |
|
|
2023
Q3 | $186K | Buy |
1,606
+911
| +131% | +$111K | 0.01% | 1475 |
|
|
2023
Q2 | $81.6K | Sell |
695
-261
| -27% | -$26.6K | ﹤0.01% | 2195 |
|
|
2023
Q1 | $77K | Buy |
956
+571
| +148% | +$44.9K | ﹤0.01% | 2107 |
|
|
2022
Q4 | $31K | Sell |
385
-3,092
| -89% | -$230K | ﹤0.01% | 2718 |
|
|
2022
Q3 | $242K | Buy |
3,477
+710
| +26% | +$51.3K | ﹤0.01% | 1732 |
|
|
2022
Q2 | $181K | Sell |
2,767
-359
| -11% | -$22.3K | ﹤0.01% | 1838 |
|
|
2022
Q1 | $208K | Sell |
3,126
-2,473
| -44% | -$154K | ﹤0.01% | 1689 |
|
|
2021
Q4 | $391K | Buy |
5,599
+3,189
| +132% | +$186K | 0.01% | 1282 |
|
|
2021
Q3 | $126K | Buy |
2,410
+558
| +30% | +$33K | ﹤0.01% | 2204 |
|
|
2021
Q2 | $126K | Buy |
1,852
+734
| +66% | +$51.2K | ﹤0.01% | 2235 |
|
|
2021
Q1 | $87K | Buy |
1,118
+474
| +74% | +$34.5K | ﹤0.01% | 2691 |
|
|
2020
Q4 | $39K | Buy |
644
+321
| +99% | +$16K | ﹤0.01% | 3344 |
|
|
2020
Q3 | $14K | Sell |
323
-3,349
| -91% | -$145K | ﹤0.01% | 3964 |
|
|
2020
Q2 | $152K | Buy |
+3,672
| New | +$177K | 0.01% | 2057 |
|
|
2020
Q1 | – | Sell |
-1,180
| Closed | -$65K | – | 3506 |
|
|
2019
Q4 | $65K | Buy |
1,180
+497
| +73% | +$24.4K | 0.01% | 1173 |
|
|
2019
Q3 | $23K | Sell |
683
-1,112
| -62% | -$49.7K | ﹤0.01% | 2372 |
|
|
2019
Q2 | $72K | Buy |
+1,795
| New | +$58.7K | ﹤0.01% | 1360 |
|
|
2019
Q1 | – | Sell |
-1,140
| Closed | -$24K | – | 4053 |
|
|
2018
Q4 | $24K | Sell |
1,140
-1,487
| -57% | -$31.1K | ﹤0.01% | 1794 |
|
|
2018
Q3 | $46K | Buy |
+2,627
| New | +$44.1K | ﹤0.01% | 1804 |
|
Other funds holding KRYS
ACA
SCM
Tower Research Capital (TRC)'s KRYS Position: Q2 2026 in Review
Tower Research Capital (TRC) reduced its Krystal Biotech (KRYS) stake by 32% in Q2 2026, selling an estimated $219K and leaving 1,585 shares worth $589K. The position accounts for 0.01% of the portfolio, ranked #921.
Tower Research Capital (TRC) first reported a position in KRYS in Q3 2018 and has held it in 30 quarters since. The position peaked at $1.1M in Q4 2024. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.
- Tower Research Capital (TRC) held 1,585 shares of Krystal Biotech worth $589K as of Q2 2026.
- Tower Research Capital (TRC) sold 733 Krystal Biotech shares in Q2 2026, an estimated $219K.
- Krystal Biotech made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #921 holding.
- Tower Research Capital (TRC) first reported a position in Krystal Biotech in Q3 2018 and has held it in 30 quarters since.
- Tower Research Capital (TRC)'s Krystal Biotech position peaked at $1.1M in Q4 2024.
- 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.